^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD80 modulator

    Related drugs:
    8d
    A Phase I Study of JLM019 Injection (clinicaltrials.gov)
    P1, N=115, Recruiting, Jecho Biopharmaceuticals Co., Ltd.
    New P1 trial
    |
    MSI (Microsatellite instability) • JAK2 (Janus kinase 2) • POLE (DNA Polymerase Epsilon) • JAK1 (Janus Kinase 1) • POLD1 (DNA Polymerase Delta 1)
    |
    MSI-H/dMMR • POLE mutation • POLD1 mutation
    3ms
    KEYNOTE-B59: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=317, Recruiting, GI Innovation, Inc. | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Oct 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)
    over2years
    First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Orca Therapeutics B.V. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Oncolytic virus
    |
    PCA3 (Prostate cancer associated 3)
    |
    ORCA-010
    4years
    First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Orca Therapeutics B.V. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Nov 2023
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    PCA3 (Prostate cancer associated 3)
    |
    ORCA-010